Rti Biologics (RTIX) 5.54 $RTIX
RTI Surgical's (RTIX) CEO Brian Hutchison On Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 12:57PM CST
RTIX: 5.54 (+0.19)
RTI Surgical tops Street 4Q forecasts
Automated Insights - Thu Feb 12, 9:01AM CST
ALACHUA, Fla. (AP) _ RTI Surgical Inc. (RTIX) on Thursday reported fourth-quarter net income of $659,000, after reporting a loss in the same period a year earlier.
RTIX: 5.54 (+0.19)
RTI Surgical beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:43AM CST
RTIX: 5.54 (+0.19)
RTI Surgical Announces 2014 Fourth Quarter, Full Year Results, 2015 Financial Guidance
Business Wire - Thu Feb 12, 7:01AM CST
--Company Will Hold Conference Call at 8:30 a.m. ET
RTIX: 5.54 (+0.19)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
RTI Surgical Schedules 2014 Fourth Quarter, Year End Earnings and Conference Call for February 12, 2015
Business Wire - Thu Feb 05, 8:00AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the fourth quarter and year end 2014 on Thursday, February 12, 2015, prior to the market open.
RTIX: 5.54 (+0.19)
Earnings Preview: Intuitive Surgical Q4 2014
Selerity Research - at Seeking Alpha - Fri Jan 16, 12:49PM CST
ISRG: 510.73 (+3.02), RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), ARAY: 8.00 (+0.24), PVG: 6.44 (-0.07), DCTH: 1.14 (+0.04)
RTI Biologics Has Returned 14.5% Since SmarTrend Recommendation (RTIX)
Comtex SmarTrend(R) - Fri Jan 09, 9:20AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 months, RTI Biologics has returned 14.48% as of today's recent price of $5.18.
RTIX: 5.54 (+0.19)
RTI Surgical Now a Strong Buy, Raised Guidance a Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 3:20PM CST
On Dec 30, 2014, Zacks Investment Research upgraded RTI Surgical Inc. (RTIX) to a Zacks Rank #1 (Strong Buy).
ETRM: 1.21 (+0.06), RTIX: 5.54 (+0.19), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32)
Mettler-Toledo Touches 52-Week High on Positive Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 7:50AM CST
Shares of Mettler-Toledo International Inc. (MTD) reached a 52-week high of $306.92 on Dec 29.
RTIX: 5.54 (+0.19), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), MTD: 307.00 (-0.13)
Shares of RTIX Up 19.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 19, 11:02AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 months, RTI Biologics has returned 19.34% as of today's recent price of $5.40.
RTIX: 5.54 (+0.19)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 45.46 (-0.33), RTIX: 5.54 (+0.19), HALO: 14.73 (+0.23), EBS: 28.76 (-0.12), ANIK: 41.30 (-0.17), MDXG: 8.65 (+0.23)
RTI Surgical Announces Retirement of Thomas F. Rose
Business Wire - Mon Dec 15, 7:30AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that Thomas F. Rose has informed the company of his intention to retire from his position as executive vice president of administration effective Dec. 31, 2014. Rose will continue to serve as corporate secretary for RTI's board of directors.
RTIX: 5.54 (+0.19)
RTI Surgical(TM) Hosts Winter Biologics Spine Symposium
Business Wire - Fri Dec 12, 3:30PM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, is hosting a surgeon education symposium focused on the use of biologic implants in spine surgery tomorrow in New York.
RTIX: 5.54 (+0.19)
RTI Biologics Shares Up 17.3% Since SmarTrend's Buy Recommendation (RTIX)
Comtex SmarTrend(R) - Fri Dec 12, 9:38AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 1 month, RTI Biologics has returned 17.35% as of today's recent price of $5.31.
RTIX: 5.54 (+0.19)
RTI Biologics Earnings In Retrospect: Up 6.3% in the Last 18 Days (RTIX)
Comtex SmarTrend(R) - Mon Nov 17, 4:02PM CST
When RTI Biologics (NASDAQ:RTIX) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $64.5 million. The company actually reported EPS of $0.03 on sales of $65.2 million, beating EPS estimates by $0.01 and beating revenue estimates by $0.6 million. Since the company's report, shares of RTI Biologics have risen from $4.76 to $5.06, representing a gain of 6.3% in the past 18 days.
RTIX: 5.54 (+0.19)
12.9% Return Seen to Date on SmarTrend RTI Biologics Call (RTIX)
Comtex SmarTrend(R) - Fri Nov 14, 9:57AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 weeks, RTI Biologics has returned 12.93% as of today's recent price of $5.11.
RTIX: 5.54 (+0.19)
RTI Surgical's (RTIX) CEO Brian Hutchison On Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 12:57PM CST
RTIX: 5.54 (+0.19)
RTI Surgical tops Street 4Q forecasts
Automated Insights - Thu Feb 12, 9:01AM CST
ALACHUA, Fla. (AP) _ RTI Surgical Inc. (RTIX) on Thursday reported fourth-quarter net income of $659,000, after reporting a loss in the same period a year earlier.
RTIX: 5.54 (+0.19)
RTI Surgical beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:43AM CST
RTIX: 5.54 (+0.19)
RTI Surgical Announces 2014 Fourth Quarter, Full Year Results, 2015 Financial Guidance
Business Wire - Thu Feb 12, 7:01AM CST
--Company Will Hold Conference Call at 8:30 a.m. ET
RTIX: 5.54 (+0.19)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
RTI Surgical Schedules 2014 Fourth Quarter, Year End Earnings and Conference Call for February 12, 2015
Business Wire - Thu Feb 05, 8:00AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the fourth quarter and year end 2014 on Thursday, February 12, 2015, prior to the market open.
RTIX: 5.54 (+0.19)
Earnings Preview: Intuitive Surgical Q4 2014
Selerity Research - at Seeking Alpha - Fri Jan 16, 12:49PM CST
ISRG: 510.73 (+3.02), RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), ARAY: 8.00 (+0.24), PVG: 6.44 (-0.07), DCTH: 1.14 (+0.04)
RTI Biologics Has Returned 14.5% Since SmarTrend Recommendation (RTIX)
Comtex SmarTrend(R) - Fri Jan 09, 9:20AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 months, RTI Biologics has returned 14.48% as of today's recent price of $5.18.
RTIX: 5.54 (+0.19)
RTI Surgical Now a Strong Buy, Raised Guidance a Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 3:20PM CST
On Dec 30, 2014, Zacks Investment Research upgraded RTI Surgical Inc. (RTIX) to a Zacks Rank #1 (Strong Buy).
ETRM: 1.21 (+0.06), RTIX: 5.54 (+0.19), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32)
Mettler-Toledo Touches 52-Week High on Positive Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 7:50AM CST
Shares of Mettler-Toledo International Inc. (MTD) reached a 52-week high of $306.92 on Dec 29.
RTIX: 5.54 (+0.19), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), MTD: 307.00 (-0.13)
Shares of RTIX Up 19.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 19, 11:02AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 months, RTI Biologics has returned 19.34% as of today's recent price of $5.40.
RTIX: 5.54 (+0.19)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 45.46 (-0.33), RTIX: 5.54 (+0.19), HALO: 14.73 (+0.23), EBS: 28.76 (-0.12), ANIK: 41.30 (-0.17), MDXG: 8.65 (+0.23)
RTI Surgical Announces Retirement of Thomas F. Rose
Business Wire - Mon Dec 15, 7:30AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that Thomas F. Rose has informed the company of his intention to retire from his position as executive vice president of administration effective Dec. 31, 2014. Rose will continue to serve as corporate secretary for RTI's board of directors.
RTIX: 5.54 (+0.19)
RTI Surgical(TM) Hosts Winter Biologics Spine Symposium
Business Wire - Fri Dec 12, 3:30PM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, is hosting a surgeon education symposium focused on the use of biologic implants in spine surgery tomorrow in New York.
RTIX: 5.54 (+0.19)
RTI Biologics Shares Up 17.3% Since SmarTrend's Buy Recommendation (RTIX)
Comtex SmarTrend(R) - Fri Dec 12, 9:38AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 1 month, RTI Biologics has returned 17.35% as of today's recent price of $5.31.
RTIX: 5.54 (+0.19)
RTI Biologics Earnings In Retrospect: Up 6.3% in the Last 18 Days (RTIX)
Comtex SmarTrend(R) - Mon Nov 17, 4:02PM CST
When RTI Biologics (NASDAQ:RTIX) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $64.5 million. The company actually reported EPS of $0.03 on sales of $65.2 million, beating EPS estimates by $0.01 and beating revenue estimates by $0.6 million. Since the company's report, shares of RTI Biologics have risen from $4.76 to $5.06, representing a gain of 6.3% in the past 18 days.
RTIX: 5.54 (+0.19)
12.9% Return Seen to Date on SmarTrend RTI Biologics Call (RTIX)
Comtex SmarTrend(R) - Fri Nov 14, 9:57AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 weeks, RTI Biologics has returned 12.93% as of today's recent price of $5.11.
RTIX: 5.54 (+0.19)
